Aoki Drug Holdings Co., Ltd. has appointed new director candidates and outside director candidates, with approval scheduled at the shareholders’ meeting on August 19, 2026. This aims to promote sustainable growth and strengthen governance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3549","jir_company_name":"Aoki Drug Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/3549-20260716-02.pdf","jir_short_summary":"Aoki Drug Holdings Co., Ltd. has appointed new director candidates and outside director candidates, with approval scheduled at the shareholders' meeting on August 19, 2026. This aims to promote sustainable growth and strengthen governance.","jir_summary":"### Overview of Executive Personnel Changes\nThis document announces that Aoki Drug Holdings Co., Ltd. has decided on the appointment of new director candidates, outside director candidates, and substitute auditor candidates in preparation for the shareholders' meeting on August 19, 2026. Four individuals\u2014Takeshi Yoshida, Yosuke Enkado, Minoru Ozawa, and Shinichi Morioka\u2014have been newly nominated as officer candidates, with some officers scheduled to retire. These personnel changes are aimed at achieving the financial targets of the company's Fourth Medium-Term Management Plan and enhancing governance. In particular, candidates with extensive experience and expertise are being appointed to accelerate management decision-making and improve supervisory functions.\n\n### Future Outlook and Corporate Strategy\nWith the appointment of new officers, the company aims for sustainable growth and improved capital efficiency by strengthening its earnings structure and actively promoting M&A activities. The company expects to receive advice and oversight from a neutral standpoint independent of the management team, contributing to increased transparency in governance. Through these efforts, the company plans to pursue more solid management toward achieving sales and profit targets.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#AokiDrug, #ExecutiveChanges, #JapanStocks","jir_key_figures":"Number of new director candidates: 4\nShareholders' meeting date: August 19, 2026\nScheduled appointment date: August 19, 2026","jir_meta_title":"\u3010Aoki Drug\u3011Executive Changes and Strengthening of Medium-Term Management Plan\uff5cJuly 2026","jir_meta_description":"Aoki Drug Holdings Co., Ltd. announces the appointment of new officer candidates and the strengthening of management strategies. Approval is scheduled at the shareholders' meeting in August 2026.","jir_og_title":"\u3010Aoki Drug\u3011Executive Changes and Management Strategies\uff5cJuly 2026","jir_og_description":"Aoki Drug announces executive personnel changes. Building a new structure aimed at sustainable growth and governance enhancement.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8062,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-81835","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n